ReWalk Robotics Ltd. (NASDAQ:RWLK) shares fell 5.4% on Wednesday . The stock traded as low as $6.60 and last traded at $6.65, with a volume of 62,477 shares traded. The stock had previously closed at $7.03.

Several research firms have weighed in on RWLK. Zacks Investment Research upgraded ReWalk Robotics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday, May 10th. Jefferies Group restated a “buy” rating and issued a $16.00 price target on shares of ReWalk Robotics in a research report on Sunday, May 8th. Finally, Piper Jaffray Cos. assumed coverage on ReWalk Robotics in a research report on Friday, July 15th. They issued an “overweight” rating and a $10.00 price target on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ReWalk Robotics presently has an average rating of “Buy” and a consensus target price of $12.80.

The company has a 50-day moving average price of $6.71 and a 200 day moving average price of $8.76. The company’s market cap is $82.27 million.

ReWalk Robotics (NASDAQ:RWLK) last posted its quarterly earnings data on Thursday, May 5th. The medical device company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.12. The business earned $2.06 million during the quarter, compared to analysts’ expectations of $1.56 million. The firm’s revenue for the quarter was up 224.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.48) EPS. On average, equities analysts expect that ReWalk Robotics Ltd. will post ($2.11) EPS for the current fiscal year.

In other ReWalk Robotics news, major shareholder Scp Vitalife Partners (Israel) sold 4,043 shares of the business’s stock in a transaction on Friday, May 20th. The stock was sold at an average price of $9.09, for a total value of $36,750.87. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeff Dykan sold 27,022 shares of the business’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $8.69, for a total value of $234,821.18. The disclosure for this sale can be found here.

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk. The Company offers ReWalk, an exoskeleton that uses its tilt-sensor technology, and an on-board computer and motion sensors to drive motorized legs that power movement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.